Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin By Ogkologos - February 23, 2026 311 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-905/EV-303 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate April 3, 2024 Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 Boy Born With Heart Defect Gets Surgery To Help It Triple... December 26, 2021 Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... August 6, 2025 Load more HOT NEWS Life-saving scheme to improve cancer screening among Muslim women Can Cancer Symptoms Be Mistaken for Menopause? Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC... Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer
